SV2002000362A -
PROTEINS THAT HAVE AN ANGIOGENESIS MODULATING ACTIVITY REF.MSB-7265-SV
- Google Patents
PROTEINS THAT HAVE AN ANGIOGENESIS MODULATING ACTIVITY REF.MSB-7265-SV
Info
Publication number
SV2002000362A
SV2002000362ASV2001000362ASV2001000362ASV2002000362ASV 2002000362 ASV2002000362 ASV 2002000362ASV 2001000362 ASV2001000362 ASV 2001000362ASV 2001000362 ASV2001000362 ASV 2001000362ASV 2002000362 ASV2002000362 ASV 2002000362A
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer CorpfiledCriticalBayer Corp
Priority to SV2001000362ApriorityCriticalpatent/SV2002000362A/en
Publication of SV2002000362ApublicationCriticalpatent/SV2002000362A/en
Medicines That Contain Protein Lipid Enzymes And Other Medicines
(AREA)
Abstract
LA BTL-012 ES UNA NUEVA PROTEINA HUMANA UTIL PARA REGULAR O MODULAR LA ANGIOGENESIS. LA BTIL-012 O SUS VARIANTES, PUEDEN EMPLEARSE COMO TERAPIA EN ENFERMEDADES COMO EL CANCER, LA CURACION DE HERIDAS, LA RETINOPATIAS DIABETICAS, LA DEGENERACION MACULAR, Y LAS ENFERMEDADES CARDIOVASCULARES Y OTRAS ENFERMEDADES O CONDICIONES CLINICAS EN LAS CUALES LA ANGIOGENESIS ES RELEVANTE A LA CAUSA O EL TRATAMIENTO DE LA ENFERMEDAD.THE BTL-012 IS A NEW HUMAN PROTEIN USEFUL TO REGULATE OR MODULATE ANGIOGENESIS. THE BTIL-012 OR ITS VARIANTS, MAY BE USED AS A THERAPY IN DISEASES AS CANCER, WOUND HEALING, DIABETIC RETINOPATHICS, MACULAR DEGENERATION, AND OTHER CARDIOVASCULAR DISEASES AND OTHER DISEASES TO LA ANGELES CAUSE OR TREATMENT OF THE DISEASE.
SV2001000362A2001-03-302001-03-30
PROTEINS THAT HAVE AN ANGIOGENESIS MODULATING ACTIVITY REF.MSB-7265-SV
SV2002000362A
(en)
The effect of narrowband ultraviolet B on the expression of matrix metalloproteinase‐1, transforming growth factor‐β1 and type I collagen in human skin fibroblasts